Market Overview:
The global acute vulvovaginal candidiasis treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of fungal infections, rising awareness about available treatments, and growing demand for over-the-counter (OTC) drugs. Based on type, the clotrimazole segment is expected to account for the largest share of the global acute vulvovaginal candidiasis treatment market in 2018. This segment is also projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. Clotrimazole is an azole antifungal agent that exhibits broad spectrum activity against Candida species and other fungi such as Aspergillus niger and Trichophyton rubrum . It is available in both oral and topical formulations, which makes it a preferred choice for treating various types of fungal infections including vaginal candidiasis . Based on application, hospital pharmacies are expected to account for the largest share of the global acute vulvovaginal candidiasis treatment market in 2018. This segment is also projected to grow at a CAGR of 5.7% during the forecast period from 2018to 2030 owingto increasing numberof hospital admissions due toreasons such as lifestyle diseasesand rising geriatric population acrossthe globe .
Product Definition:
Acute Vulvovaginal Candidiasis Treatment is a form of treatment used to treat acute vulvovaginal candidiasis, which is a type of yeast infection. This type of infection can cause symptoms such as itching, burning, and pain in the vaginal area, as well as thick discharge. The Acute Vulvovaginal Candidiasis Treatment may include the use of antifungal medications such as fluconazole or itraconazole, either orally or vaginally.
Clotrimazole:
Clotrimazole is an anti-fungal medication used to treat vaginal yeast infections. It works by killing the fungal cells that are causing the infection. The drug has a wide spectrum of activity against various pathogenic fungi, including Candida albicans and other aniomic molds.
Nystatin:
Nystatin is an antifungal medication used for the treatment of vaginal candidiasis. It works by killing the fungal infection. The drug has a wide spectrum of activity against various species of pathogenic fungi, including Candida albicans and other anamorphic yeasts such as C. tropicalis and C. parvum (classical).
Application Insights:
The acute vulvovaginal candidiasis treatment market by application is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment dominated the global market in 2017 due to factors such as a high prevalence of patients suffering from AVD and increasing awareness among healthcare professionals regarding the availability of effective treatment options for this disease.
According to research studies, approximately 1 in 5 women get some form of yeast infection during their lifetime. Yeast infections are very common; however, most women have no idea that it can be treated easily at home with over-the-counter products without visiting a doctor or pharmacist. This has led many manufacturers to launch new products specifically designed for home treatment of AVD under the guidance of pharmacists or doctors.
Regional Analysis:
North America dominated the global market in 2017. This is due to high incidence of Candida albicans and other vulvovaginal infections, increasing use of clotrimazole, fluconazole, ketoconazole and nystatin for treatment of CVID in U.S., Canada and Mexico as well as presence of key manufacturers such as Pfizer Inc.; Mylan N.V.; Apotex Inc.; Dr. Reddy's Laboratories Ltd; VIVUS Inc; Aurobindo Pharma USA LLC; Actavis plc; Mallinckrodt Plc among others that are engaged in promoting awareness regarding acute vulvovaginal candidiasis treatment options through various programs & activities such as product launches, strategic partnerships & mergers etc.
Growth Factors:
- Increasing incidence of acute vulvovaginal candidiasis (AVVC) due to changing lifestyle and dietary habits
- Growing awareness about the symptoms and treatment of AVVC among patients and healthcare professionals
- Rising demand for effective and safe AVVC treatments, especially from emerging markets
- Technological advancements in the field of AVVC treatment that offer better patient outcomes
- increasing number of mergers & acquisitions, collaborations, and partnerships between pharmaceutical companies to develop novel therapies for AVVC
Scope Of The Report
Report Attributes
Report Details
Report Title
Acute Vulvovaginal Candidiasis Treatment Market Research Report
By Type
Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc, Amplyx Pharmaceuticals Inc, Pfizer, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
131
Number of Tables & Figures
92
Customization Available
Yes, the report can be customized as per your need.
Global Acute Vulvovaginal Candidiasis Treatment Market Report Segments:
The global Acute Vulvovaginal Candidiasis Treatment market is segmented on the basis of:
Types
Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Mycovia Pharmaceuticals, Inc
- Scynexis, Inc
- Basilea Pharmaceutica Ltd
- Astellas Pharma Inc
- Grupo Ferrer Internacional, S.A
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc
- Cidara Therapeutics, Inc
- Amplyx Pharmaceuticals Inc
- Pfizer, Inc.
Highlights of The Acute Vulvovaginal Candidiasis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acute Vulvovaginal Candidiasis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acute vulvovaginal candidiasis (AVC) is a fungal infection of the vagina. It is most commonly caused by Candida albicans, but can also be caused by other fungi. AVC affects up to 50% of women in their lifetime and is one of the most common vaginal infections. Treatment typically involves antifungal medication taken for several weeks or months.
Some of the major players in the acute vulvovaginal candidiasis treatment market are Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc, Amplyx Pharmaceuticals Inc, Pfizer, Inc..
The acute vulvovaginal candidiasis treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acute Vulvovaginal Candidiasis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acute Vulvovaginal Candidiasis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acute Vulvovaginal Candidiasis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acute Vulvovaginal Candidiasis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acute Vulvovaginal Candidiasis Treatment Market Size & Forecast, 2018-2028
4.5.1 Acute Vulvovaginal Candidiasis Treatment Market Size and Y-o-Y Growth
4.5.2 Acute Vulvovaginal Candidiasis Treatment Market Absolute $ Opportunity
Chapter 5 Global Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Type
5.2.1 Clotrimazole
5.2.2 Nystatin
5.2.3 Fluconazole
5.2.4 Ketoconazole
5.2.5 Terbinafine
5.2.6 Terconazole
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Acute Vulvovaginal Candidiasis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Type
9.6.1 Clotrimazole
9.6.2 Nystatin
9.6.3 Fluconazole
9.6.4 Ketoconazole
9.6.5 Terbinafine
9.6.6 Terconazole
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Acute Vulvovaginal Candidiasis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Type
10.6.1 Clotrimazole
10.6.2 Nystatin
10.6.3 Fluconazole
10.6.4 Ketoconazole
10.6.5 Terbinafine
10.6.6 Terconazole
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Acute Vulvovaginal Candidiasis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Type
11.6.1 Clotrimazole
11.6.2 Nystatin
11.6.3 Fluconazole
11.6.4 Ketoconazole
11.6.5 Terbinafine
11.6.6 Terconazole
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Acute Vulvovaginal Candidiasis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Type
12.6.1 Clotrimazole
12.6.2 Nystatin
12.6.3 Fluconazole
12.6.4 Ketoconazole
12.6.5 Terbinafine
12.6.6 Terconazole
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Acute Vulvovaginal Candidiasis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Type
13.6.1 Clotrimazole
13.6.2 Nystatin
13.6.3 Fluconazole
13.6.4 Ketoconazole
13.6.5 Terbinafine
13.6.6 Terconazole
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Acute Vulvovaginal Candidiasis Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acute Vulvovaginal Candidiasis Treatment Market: Competitive Dashboard
14.2 Global Acute Vulvovaginal Candidiasis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Mycovia Pharmaceuticals, Inc
14.3.2 Scynexis, Inc
14.3.3 Basilea Pharmaceutica Ltd
14.3.4 Astellas Pharma Inc
14.3.5 Grupo Ferrer Internacional, S.A
14.3.6 Pacgen Life Science Corporation
14.3.7 NovaDigm Therapeutics, Inc
14.3.8 Cidara Therapeutics, Inc
14.3.9 Amplyx Pharmaceuticals Inc
14.3.10 Pfizer, Inc.
